EyeWorld India December 2021 Issue

CATARACT EWAP DECEMBER 2021 15 that in the near term this will increase peace of mind for patients and doctors, and in the long term may be a pathway toward removing the need for UV-blocking glasses. Dr. Loden added that there has also been a recent upgrade to the software for treatment of astigmatism down to 0.5 D. Dr. Ristvedt said she thinks ActivShield helps patients and prevents premature lock-in. “I think that’s one of the things that the company has been thinking about,” she said. “They’re thinking about the flow and patients having to be tied to wearing ultraviolet glasses and getting treatments consecutively.” Dr. Chang also noted the recent FDA approval of the ActivShield. “Although the label still specifies UV glasses, Arturo Chayet, MD, has used this LAL version in a series of patients without them wearing any UV glasses,” Dr. Chang said. “If UV glasses eventually turn out to be unnecessary, this would be a revolutionary advance in the technology.” He also mentioned that RxSight has developed an EDOF adjustment that could be centered on the visual axis of the near eye postoperatively. “This would be of enormous value in reducing the amount of myopia needed to provide functional reading ability,” he said. “These innovations will make the technology even more attractive to our refractive patients.” How does Perfect Lens differ from the LAL? Another adjustable technology in development is Perfect Lens. Dr. Chang said this system would modify the IOL power and design using an in situ femtosecond laser treatment. The technology has been tested in animals and testing in human eyes is just underway, he said. Dr. Loden said he thinks Perfect Lens and LAL are two very different products. The LAL is a silicone three-piece lens that adjusts its power with UV light. The Perfect Lens is a femtosecond laser that is used to change the refractive index of a lens that has been already implanted in order to adjust the power of the IOL. Dr. Naids said the idea of the Perfect Lens being able to modify an existing IOL would open up the possibility of lens changes based on patient preference and could help with refractive misses/IOL exchanges. It sounds promising, he said, but he noted that he still thinks LAL will have a place in the treatment paradigm, especially since it’s continuing to get better. “We have something that we know is viable and gives us good results,” he said. EWAP Editors’ note: Dr. Chang is Clinical Professor of Ophthalmology, University of California, San Francisco, San Francisco, California, and has interests with RxSight and Perfect Lens. Dr. Loden practices at Loden Vision Centers, Nashville, Tennessee, and declared no relevant financial interests. Dr. Naids practices at Advanced Vision Care, Los Angeles, California, and declared no relevant financial interests. Dr. Ristvedt practices at Vance Thompson Vision, Alexandria, Minnesota, and declared no relevant financial interests. Deadline: 20 February 2022 11-12 June 2022 A N e w D a w n Abstract submission now open! Jointly organized by Visit our website at www.apacrs2022.org for more information. 34 APACRS Seoul, South Korea Annual Meeting of the Asia-Pacific Association of Cataract & Refractive Surgeons th abstract submission2.indd 3 23/11/2021 2:12 PM